A good start to the week that we should ideally build upon. We are certainly heading to a period of strength for the sector (or at least should be). It was the last quarter of last year in which we got all of the gains for the year. It is setting up to be that […]
October 11th Biotech Update
Hopefully we can end the week on a high note both figuratively and literally. I still think that we probably need M&A to pick up for the sector to really catch a bid. I do not think we necessarily move lower but it really is time for some deals. Of course, the Fed was a […]
October 10th, Biotech Update
We certainly seem to be setting up a range bound market instead of that uptrend that I ideally thought could develop. While not the best case scenario, it is also not the worst case. I think the lack of news and M&A might be stalling the market and perhaps we need the return of deals […]
October 7th Biotech Update
Perhaps we are trying to setup a higher low but the sector seems to be struggling a little to get a lot of traction. I do not worry too much about it as long as the recent low holds but we have been hanging out at these levels for a little too long for complete […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
